Clinical trial · Observational
Study of Pregnancy in Patients With Myeloproliferative Neoplasms
A Prospective Multicentre Study to Evaluate Maternal and Perinatal Outcomes in Myeloproliferative Neoplasms: MAPP-MPN Trial
NCT07832513CI-TRIAL-00126510not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
This is a study to evaluate pregnancy in patients with myeloproliferative neoplasms. The main endpoint of this study is to determine the number of live births in pregnant MPN patients who are managed by a risk-adapted algorithm
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloproliferative Neoplasm (MPN) | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
| Pregnancy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Risk-adapted algorithm | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants with myeloproliferative neoplasms and are pregnant
- interventionNames
- Other: Risk-adapted algorithm
Primary outcomes (1)
- measure
- Proportion of pregnancies resulting in live birth
- timeFrame
- 3 years
Secondary outcomes (7)
- measure
- Number of perinatal venous thrombotic events
- timeFrame
- 3 years
- measure
- Number of arterial thromboembolic events
- timeFrame
- 3 years
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of chronic phase essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic or overt primary myelofibrosis (PMF), post-ET myelofibrosis (MF), post-PV MF, or myeloproliferative neoplasm (MPN) - unclassifiable according to the 2022 International Consensus Criteria. Patients who have not had a diagnostic bone marrow biopsy may participate if there is a driver mutation and all other diagnostic criteria are met. * Patients with a confirmed pregnancy through Beta Human Chorionic Gonadotropin (BHCG) testing of the urine or blood and/or dating ultrasound. Patients may be eligible to participate at any stage of pregnancy. * Patients must have the ability to participate in study procedures. * Participants must provide consent to participate in this study. Exclusion Criteria: * Patients with a diagnosis of chronic myeloid leukemia, myelodysplastic syndrome (MDS), MDS/MPN overlap syndrome, or other myeloid malignancy. * Peripheral blood or marrow blasts \>/= 10%. * Patients with concurrent disease that in the opinion of the investigator may be adversely impact the safety of the patient or impair assessment of study results, including but not limited to: * Uncontrolled autoimmune diseases (e.g., hepatitis, immune thrombocytopenic purpura \[ITP\], scleroderma, autoimmune arthritis) * Active, uncontrolled infection (e.g., HIV, hepatitis B, hepatitis C) * Second malignancy requiring concurrent treatment, except basal cell carcinoma or squamous cell carcinoma or cervical carcinoma in situ. * Patients requiring a legally authorized representative.
References
Publications (0)
Data not yet available
No reference posted for this study.